Results for "dalbavancin"
Showing Results 1 - 15 for dalbavancin
-
Dalbavancin - Wikipedia, the free encyclopedia
Dalbavancin: A Novel Lipoglycopeptide Antibacterial ... Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial" ...
en.wikipedia.org -
Dalbavancin New Drug Application
Dalbavancin side effects, interactions, indications ... Pfizer Receives Approvable Letter from FDA for Dalbavancin - December 21, 2007 ...
www.drugs.com -
Dalbavancin New Drug Application
Dalbavancin information includes news, clinical trial results and side effects. ... Pfizer Receives Approvable Letter from FDA for Dalbavancin - December 21, 2007 ...
www.drugs.com -
Dalbavancin: a novel antimicrobial
Dalbavancin is the first once a week antibiotic with activity against a broad ... Like other glycopeptides, dalbavancin's mechanism of action involves the ...
www.pubmedcentral.nih.gov -
Dalbavancin: A Novel Lipoglycopeptide Antibacterial
This novel agent currently in Phase III trials could provide an important alternative in treating resistant gram-positive infections.
www.medscape.com -
Health Links Content: Focus On: Dalbavancin A novel long-acting ...
Dalbavancin (Pfizer) is a new lipoglycopeptide antibiotic in phase 3 trials for ... Peak concentrations of dalbavancin occur immediately following infusion and ...
healthlinks.mediwire.com -
Factors Influencing Broth Microdilution Antimicrobial Susceptibility ...
Dalbavancin is a new glycopeptide with potent activity against gram-positive bacterial species. ... Dalbavancin also readily adsorbs to plastic surfaces, ...
www.pubmedcentral.nih.gov -
BioWorld Today
Dalbavancin was dosed once a week for two weeks, while linezolid, cefazolin and ... Dalbavancin is a next-generation glycopeptide agent that belongs to the same ...
www.bioworld.com -
Pfizer withdraws dalbavancin app - FierceBiotech
Pfizer has withdrawn U.S. and European marketing applications for dalbavancin--a drug for complicated skin and skin structure infections in adults--following ...
www.fiercebiotech.com -
Dalbavancin: A review for dermatologists
Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed ... The side effect profile of dalbavancin is mild, with headache and pyrexia being ...
dermatology.cdlib.org -
Bloomberg.com: Worldwide
Credit-Default Swaps Outstanding Top $33 Trillion, Depository Trust Says. Currency Derivatives Face Curbs in Korea, China, Hong Kong After Losses ...
www.bloomberg.com -
Pfizer Will Withdraw Global Marketing Applications For Dalbavancin To ...
Pfizer Inc announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, ...
www.medicalnewstoday.com -
REG-Pfizer Inc Pfizer Receives Approvable Letter from FDA for ...
... Drug Administration (FDA) issued for dalbavancin HCl, Pfizer's once-weekly two-dose ... Dalbavancin, a member of the glycopeptide class of antibiotics, ...
www.reuters.com -
A New Antibiotic – Dalbavancin – Has Favorable Ecological Properties
Dalbavancin is a new lipoglycopeptide antibiotic active in vitro against most ... Plasma dalbavancin concentrations at 2, 14 and 60 d after administration were ...
www.asm.org -
Forbes.com: Vicuron Advances With Dalbavancin
... positive results for its dalbavancin antibiotic and said it would file a new ... open, Vicuron announced that dalbavancin, its long-acting glycopeptide ...
www.forbes.com
| Next Results >> |
